OncoPharm

Small cell lung cancer is reviewed, including the milestone advances (chemo + RT, omitting surgery, cis/etoposide) of the past leading up to the latest advance (15:20) - FDA-approval of nivolumab in the 3rd-line setting.

Mogamulizumab-kpkc (MOAs, administration, toxicity) and its FDA-approval is discussed followed by (9:00) updates lenvatinib (a good update) and azithromycin (a bad update) in cancer patients.

Dive into the fascinating journey of rituximab from its dosage origins to its pivotal role in treating B-cell malignancies. The discussion highlights key insights from early clinical trials that shaped current practices. Listeners will also geek out over the latest data on the number needed to treat (NNT) in diffuse large B-cell lymphoma (DLBC). Plus, learn about rituximab's mechanisms, potential side effects, and essential infusion management tips.

Catching up the recent FDA-approvals for iobenguane I-131 (and its myriad of precautions) and lusutrombopag.

After running through recent FDA updates (including ribociclib's approval in PRE-menopausal breast cancer patients), the newly approved ivosidenib is discussed.

Explore the fascinating journey of pemetrexed, a drug that transformed non-small cell lung cancer treatment. Discover its roots in clinical trials starting in 1995 and the groundbreaking findings that emerged a decade later. The discussion highlights a pivotal 2008 study that ushered in histology-specific treatment approaches, illustrating how research can reshape medical practice. Tune in for insights into how these developments have influenced the lives of patients and the oncology landscape.

We discuss paclitaxel, from its discovery to its uses to toxicity and their management as part of our Landmarks in #OncoPharm series. And if you really, really love this drug - you'll learn where to may homage at a historical marker in....

Our shortest Pod yet! Chemotherapy explosions and photosensitizing antineoplastics are discussed.

The newly FDA-approved BRAF & MEK inhibitors are discussed, along with their possible clinical relevance and some notable differences compared to previously available BRAF & MEK inhibitors.

Immunotherapy takes two steps forward (new FDA approvals)....and two steps backwards. These updates in #oncopharm are discussed before ending (11:45) with discussions of venetoclax's expanded approval in CLL, the bevacizumab approval almost 7 years in the making, and late-breaking information on preventing cisplatin ototoxicity.